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Objectives The purpose of this study was to examine prospectively whether inflammation explains the relationship between
depression and cardiovascular disease (CVD).
Background It is unclear whether inflammation is a mechanism linking depression to CVD.
Methods We measured C-reactive protein (CRP) and interleukin (IL)-6 in 559 women with suspected coronary ischemia
who completed the Beck Depression Inventory (BDI) at baseline and were followed over 5.9 years. We consid-
ered indicators of past and current depression to classify women into 3 groups: 1) depression, having both ele-
vated depressive symptoms (BDI 10) and a previous diagnosis of depression requiring treatment; 2) possible
depression, having either indicator but not both; and 3) no depression, having neither indicator of depression.
The main outcome was incidence of CVD events (hospital stays for nonfatal myocardial infarction, stroke, con-
gestive heart failure, and CVD-related mortality).
Results Compared with women without depression, women with depression had a 70% higher CRP (p  0.0008) and a
25% higher IL-6 (p  0.04), whereas women with possible depression had 30% higher CRP (p  0.02) and 28%
higher IL-6 (p  0.01). Depression was a significant predictor of CVD (hazard ratio 2.58, p  0.0009), but possi-
ble depression was not (hazard ratio 1.12, p  0.68). Adjustment for other patient factors did not substantially
affect the results. Addition of CRP decreased the estimate for depression by 13% and addition of IL-6 decreased
it by 4%. Both depression and inflammatory biomarkers remained independent predictors of outcome.
Conclusions Despite their robust association with depression, inflammatory biomarkers explain only a small portion of the
association between depression and CVD incidence. (J Am Coll Cardiol 2007;50:2044–50) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.069h
w
a
N
c
N
D
N
P
tajor depression is common in cardiac patients, particularly
mong women (1–3), and both clinical depression and
levated depressive symptoms have been associated with a
rom the *Department of Medicine, Division of Cardiology, Emory University
chool of Medicine, Atlanta, Georgia; †Department of Epidemiology and ‡Cardio-
ascular Institute, Department of Medicine, University of Pittsburgh, Pittsburgh,
ennsylvania; §Department of Medicine, Division of Cardiovascular Medicine,
niversity of Florida, Gainesville, Florida; Department of Medicine, Division of
ardiovascular Disease, University of Alabama at Birmingham, Birmingham, Ala-
ama; ¶University of California, San Diego, California; #Department of Medicine,
ivision of Cardiology, Cedars-Sinai Research Institute, Cedars-Sinai Medical
enter, Los Angeles, California; and the **National Heart, Lung, and Blood Institute, aigher risk of adverse outcome events in both men and
omen (4–6). However, the mechanisms underlying this
ssociation remain unclear (7).
ational Institutes of Health, Bethesda, Maryland. This work was supported by
ontracts from the National Heart, Lung, and Blood Institute N01-HV-68161,
01-HV-68162, N01-HV-68163, and N01-HV-68164; grant K24HL077506 (to
r. Vaccarino); a General Clinical Research Center grant M01-RR00425 from the
ational Center for Research Resources; and grants from the Gustavus and Louis
feiffer Research Foundation, The Women’s Guild, Cedars-Sinai Medical Center,
he Ladies Hospital Aid Society of Western Pennsylvania, and QMED, Inc.
Manuscript received May 2, 2007; revised manuscript received July 12, 2007,
ccepted July 30, 2007.
p
y
s
d
e
m
s
s
l
d
p
b
p
t
d
t
a
b
p
i
p
c
i
F
s
C
w
r
a
a
e
d
p
M
S
(
t
B
e
m
p
y
t
c
b
t
s
c
h
n
r
p
b
h
t
e
w
b
w
D
v
o
d
M
O
c
(
s
m
s
i
e
s
s
s
s
1
n
(
d
a
r
d
p
s
t
(
s
c
w
d
1
i
n
2
p
d
n
m
c
M
a
m
s
n
S
2045JACC Vol. 50, No. 21, 2007 Vaccarino et al.
November 20, 2007:2044–50 Depression, Inflammation, and CVDRecently, clinical depression and elevated levels of de-
ressive symptoms were linked to inflammation, in both
ounger (8,9) and older (10–12) community-dwelling per-
ons. A similar association was observed in patients with a
iagnosis of major depression during an active depressive
pisode (13–16). Given the well-established role of inflam-
ation in the pathogenesis and risk prediction of athero-
clerotic cardiovascular disease (CVD) and acute coronary
yndromes (17–20), it is possible that inflammation modu-
ates the relationship between depression and CVD inci-
ence or mortality. This question is fundamentally unex-
lored, because prospective studies have rarely included
oth depression and inflammatory markers as covariables in
rediction models for incident CVD events (21). In addi-
ion, the exact nature of the inter-relationships among
epression, inflammation, and outcome is not well charac-
erized. Specifically, it is not clear to what extent these
ssociations are due to coexisting risk factors and comor-
idity or greater severity of atherosclerotic disease among
ersons with depression (21).
The purpose of this study was to explore the role of
nflammation in explaining the relationship between de-
ressive symptoms and major outcome events in a well-
haracterized sample of women with suspected coronary
schemia, a group distinctively affected by depression (3).
irst, we sought to determine whether, at baseline, depres-
ive mood was associated with 2 inflammatory markers,
-reactive protein (CRP) and interleukin (IL)-6, and to
hat extent this relationship was due to concurrent CVD
isk factors and comorbidity and to severity of coronary
rtery disease (CAD) measured by quantitative coronary
ngiography. Second, we sought to determine to what
xtent inflammation modulates the association between
epressive mood and outcome after adjusting for other
atient factors.
ethods
tudy sample and general procedures. The WISE
Women’s Ischemia Syndrome Evaluation) study is a mul-
icenter study sponsored by the National Heart, Lung, and
lood Institute designed to address ischemic heart disease
valuation in women. Details of the WISE study design and
ethods have been published (22). Women were eligible for
articipation in the WISE study if they were older than 18
ears of age and were referred for a coronary angiogram for
he evaluation of chest pain symptoms or suspected myo-
ardial ischemia. Exclusion criteria included major comor-
idity compromising follow-up, pregnancy, contraindica-
ions to provocative diagnostic testing, cardiomyopathy,
evere heart failure, recent myocardial infarction or revas-
ularization procedures, significant valvular or congenital
eart disease, and a language barrier preventing question-
aire completion. The WISE study received institutional
eview board approval from each participating site, and all
articipating women provided informed consent. sAll participants completed a
aseline evaluation including
ealth status, psychosocial fac-
ors, medical history, physical
xam, use of medications in past
eek, and collection of fasting
lood samples. Physical function
as assessed by means of the
uke Activity Status Index, a
alidated 12-item questionnaire
f functional capability for car-
iac patients (23).
easurement of depression.
f the 936 participants enrolled in the WISE study, 674
ompleted at baseline the Beck Depression Inventory (BDI)
24), a self-administered validated 21-item scale of depres-
ive symptoms that was shown to predict CVD outcomes in
any studies (25,26). The BDI was available only in this
ubset, because the psychological assessment battery was
ntroduced slightly later (4 months), after the WISE study
nrollment had begun. The BDI provides a continuous
core of depressive symptoms ranging from 0 to 63, and a
core 10 indicates at least moderate symptoms of depres-
ion. If more than 2 BDI questions were missing, the BDI
core was set to missing (n  20 women); however, if only
to 2 questions were missing, the mean response from the
on-missing questions was substituted to the missing values
n  41 women). A lifetime history of major depressive
isorder was not formally assessed, but participants were
sked whether they had a previous diagnosis of depression
equiring treatment. Patients were not queried about type or
uration of the treatment. We considered, consistent with
revious work (27), the concomitant presence of 2 depres-
ion indicators, a previous diagnosis of depression requiring
reatment, and currently elevated depressive symptoms
BDI 10). This classification should better capture long-
tanding or recurrent depression, which presumably in-
luded many cases of major depressive disorder. This group
as previously shown to have a remarkably higher risk of
eath and cardiac events compared with having none or only
depression indicator (27). Thus, women were classified
nto 3 groups: 1) no depression, having neither a BDI 10
or a previous diagnosis of depression requiring treatment;
) possible depression, having either a BDI 10 or a
revious diagnosis of depression but not both; and 3)
epression, having both a BDI 10 and a previous diag-
osis of depression. As part of the baseline examination, all
edications taken within the previous 6 weeks were re-
orded and classified, including antidepressant medications.
easurement of inflammatory markers. Plasma sampled
t baseline was frozen at 70°C for subsequent measure-
ent of inflammatory markers. Levels of IL-6 were mea-
ured with a commercially available enzyme-linked immu-
osorbent assay kit (Quantikine hs human IL-6, R&D
ystems, Minneapolis, Minnesota). Levels of high-
Abbreviations
and Acronyms
BDI  Beck Depression
Inventory
CAD  coronary artery
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
HR  hazard ratio
IL  interleukinensitivity CRP were measured by a high-sensitivity method
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Depression, Inflammation, and CVD November 20, 2007:2044–50n the Hitachi 911 analyzer (Roche, Basel, Switzerland)
ith reagents from Denka Seiken (Niigata, Japan).
nterleukin-6 was measured at the University of Pittsburgh,
nd CRP was assayed at a core laboratory (Brigham and
omen’s Hospital, Boston, Massachusetts) with previously
alidated techniques (28).
ssessment of angiographic CAD. Quantitative analysis
f coronary angiograms was performed off-line at the WISE
ngiographic Core Laboratory (Rhode Island Hospital,
rovidence, Rhode Island) by investigators blinded to all
ther subject data (29). Luminal diameter was measured at all
tenoses and at nearby reference segments with an electronic
ine projector-based “cross-hair” technique (Vanguard Instru-
ent Corp., Melville, New York). A CAD severity score was
eveloped by assigning increasing points to increasing percent
tenosis (0% to 19%, 20% to 49%, 50% to 69%, 70% to 89%,
0% to 98%, and 99% to 100%), after adjusting for presence of
ollaterals. Lesion location was taken into account in the
coring, with more proximal lesions receiving higher
eighting.
scertainment of CVD outcome events. Follow-up for
he occurrence of CVD events was obtained by telephone
nterview at 6 weeks and then yearly thereafter. With a
cripted interview, an experienced nurse or physician que-
ied each patient for the occurrence of and reasons for
ospital stays. The outcome of interest was a composite end
oint of major cardiovascular events, including death due to
VD or hospital stays for nonfatal myocardial infarction,
troke, or congestive heart failure (International Classifica-
ion of Diseases, Ninth Revision, codes 390 to 459). In the
vent of death, a death certificate was obtained and the
ause of death was blindly reviewed by an events committee.
n case of disagreement, a consensus and final adjudication
ere obtained by the steering committee. The median
ength of follow-up for ascertainment of survival was 5.9
ears (interquartile range 3.6 to 6.9 years).
tatistical methods. First, we performed a descriptive
omparison of baseline factors according to depression
tatus with analysis of variance models or chi-square tests.
o calculate trend statistics, we used the Mantel-Haenszel
est for categorical data and the Jonckheere-Terpstra
ethod for continuous data (30). Because the distribution
f the inflammatory markers was skewed, analyses of these
ariables were based on natural log transformations. To ease
nterpretation, values were transformed back to the original
nits yielding geometric means.
We fitted linear regression models to test the association
etween depression group and CRP or IL-6, respectively,
fter adjusting sequentially for other baseline variables.
ecause the dependent variables were log-transformed, we
xpressed the results in terms of percent change by taking
he antilog of the regression coefficient. Analyses were
onducted in the following separate steps: 1) depression
roup as sole explanatory variable; 2) demographic factors
age, race, education, marital status) were added; 3) CVD
isk factors (history of diabetes, history of hypertension, 0lasma cholesterol and high-density lipoprotein cholesterol
evels, body mass index, and current smoking) were added;
nd 4) the CAD severity score was added. At each step, we
e-examined the association between depression group and
nflammatory markers. Additional analyses were conducted
ith BDI as a continuous variable.
The relationship among depression, inflammation, and
ncident CVD events was tested with Cox proportional
azards models, which allowed us to obtain the hazard ratio
HR) and the 95% confidence interval (CI) of CVD events
ssociated with depression group before and after adjusting for
ther factors. In separate steps, as in the preceding description,
odels were adjusted for demographic factors, CVD risk
actors, and CAD severity score. Finally, inflammatory vari-
bles were added (in separate models) to determine whether
hey modulated the association between depression and out-
ome after other baseline factors were adjusted for. The
roportional hazards assumption of invariant HR over the
ollow-up was tested and found to be met.
Because the WISE study sample includes both women
ith and without obstructive CAD, and because presence of
AD might affect the levels of inflammatory biomarkers
nd of depressive symptoms and their inter-relationships,
e repeated the Cox proportional hazards analysis in the
ubgroup of women without obstructive CAD, defined as
resence of at least 1 stenosis 50% in diameter. All
nalyses were conducted with SAS software, version 9 (SAS
nstitute, Cary, North Carolina), and all tests for statistical
ignificance were 2-tailed at an alpha level of 0.05.
esults
f the 674 women who completed the BDI, 559 (83%) had
3 missing BDI items and had data on depression history,
n CVD outcome events, and on at least 1 inflammatory
arker. An additional 23 women were excluded from all
ultivariable models because of missing covariable data,
eaving 536 women available for multivariable analysis, of
hich 527 had data on CRP and 493 had data on IL-6.
Women with elevated BDI score or a previous depression
iagnosis were younger, less educated, and more likely to
moke and have hypertension than women without depres-
ion (Table 1). They also reported more angina than women
ithout depression although were not more likely to have
bstructive CAD.
ssociation between depression and inflammation. Both
epression groups were significantly associated with inflam-
atory biomarkers (Table 2). Compared with non-
epressed women, those with possible depression (having
ither a BDI 10 or a previous depression diagnosis but not
oth) showed 30% higher CRP level (p  0.02) and 28%
igher IL-6 (p  0.01). Women with depression (having
oth a BDI 10 and a previous depression diagnosis) had a
0% higher CRP (p 0.0008) and a 25% higher IL-6 (p
.04). Adjustment for CVD risk factors, comorbidity,
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November 20, 2007:2044–50 Depression, Inflammation, and CVDealth status, and CAD severity did not substantially
hange these associations.
Depressive symptoms as a continuous variable were also
ssociated with inflammation: after adjusting for all the
actors listed in Table 2, 1 SD-higher BDI score was
ssociated with 12% higher IL-6 (p  0.004) and 13%
igher CRP (p  0.04).
epression, inflammation, and incident CVD. During the
.9 years of follow-up, there were 79 outcome events,
ncluding 23 CVD deaths and 56 nonfatal CVD events. In
nadjusted analysis, women with depression had a HR of
.56 for CVD (95% CI 1.44 to 4.51) compared with women
ithout depression, whereas women with possible depres-
ion did not show a significantly elevated risk (HR 1.12,
5% CI 0.66 to 1.90) (Table 3). In exploratory analyses, we
xamined the event subcomponents of the combined CVD
nd point for their individual relationship with depression.
xcept for nonfatal stroke, all event types showed a trend for
n increased rate in the depression group.
Adjustment for demographic factors, traditional CVD
isk factors, and CAD severity score did not substantially
ffect the study estimates for the relationship between
epression group and CVD incidence (Table 3). Addition
f CRP, however, decreased slightly the estimate for de-
ression, by 13%. When IL-6 was added in place of CRP,
t decreased the estimate for depression by 4%. In these
istribution of Baseline Factors According to Depression Status
Table 1 Distribution of Baseline Factors According to Depressi
No Depression
(n  265)
Age, yrs 59.2  11.5
White, % 86
 high school education, % 85
Married, % 67
Diabetes mellitus, % 19
Hypertension, % 53
Total cholesterol, mg/dl 195  41
HDL-C, mg/dl 55  13
Body mass index, kg/m2 29.1  6.4
Current smoker, % 11
Use of aspirin in past week, % 63
Use of statins in past week, % 26
Angina frequency (1 or more daily episode), % 32
Antidepressant medications in past 6 weeks, % 4
Mean BDI 4.8  2.7
IL-6, pg/ml (geometric mean  SD) 2.6  2.2
CRP, mg/l (geometric mean  SD) 2.9  3.3
CAD at coronary angiography, %
Absent 41
Minimal 26
Obstructive 33
CAD severity score 13.8  13.2
o depression: Beck Depression Inventory (BDI) 10 and no previous depression diagnosis; possib
iagnosis.
ANOVA  analysis of variance; CAD  coronary artery disease; CRP  C-reactive protein; HDL-Codels, CRP (HR 1.27, 95% CI 1.04 to 1.55) and IL-6 dHR 1.41, 95% CI 1.05 to 1.88) remained significantly
ssociated with the outcome, independent of depression and
f all the other variables in the models.
Restricting the analysis to women without obstructive
AD did not decrease the strength of the association
etween depression and outcome (Table 3). In this group,
omen with depression had more than 3-fold higher risk of
VD compared with nondepressed women (p  0.002).
ddition of CRP, again, decreased the estimate by approx-
mately 13%, and addition of IL-6 decreased it by 4%. The
nteraction between depression group and CAD status was
ot significant in any of the models.
iscussion
n a prospective study of women with well-characterized
VD risk status, we found a significant association
etween depression, defined as having elevated depressive
ymptoms and a previous depression diagnosis, and 2
stablished biomarkers of inflammation, IL-6 and CRP.
his association was not explained by CVD risk factors,
omorbidity, and CAD severity. We also found that,
espite being associated with each other, depression and
nflammation predicted future events for the most part
ndependently. Thus, despite a clear relationship between
atus
ble Depression
(n  211)
Depression
(n  83)
p Value
ANOVA or
Chi-Square Trend
.8  11.5 53.9  10.2 0.0009 0.0008
78 84 0.056 0.21
80 77 0.13 0.049
59 61 0.22 0.18
28 20 0.056 0.37
53 72 0.004 0.009
92  45 202  47 0.22 0.86
53  11 54  13 0.12 0.14
.7  6.7 29.6  6.2 0.55 0.32
20 32 0.0001 0.0001
57 48 0.056 0.02
31 20 0.14 0.75
37 49 0.01 0.004
18 60 0.0001 0.0001
.0  7.1 20.0  8.4 0.0001 0.0001
.3  2.1 3.2  2.4 0.001 0.0008
.1  3.6 5.3  3.2 0.0001 0.0001
37 46 0.11 0.38
26 34
37 20
.0  13.9 10.0  8.6 0.047 0.41
ession: BDI 10 or previous depression diagnosis; depression: BDI 10 and previous depression
h-density lipoprotein cholesterol; IL  interleukin.on St
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Depression, Inflammation, and CVD November 20, 2007:2044–50inor role in the higher risk of adverse outcomes for
omen with depression.
Many previous studies examined the link between depres-
ion (or depressive symptoms) and CVD (31,32). However,
nly 1 previous investigation, among men, assessed the joint
Relationship Between Depression Group and Infl
Table 2 Relationship Between Depression G
% Difference
in CRP
Unadjusted
No depression Ref
Possible depression 30%
Depression 70%
p for trend
Adjusted for demographic factors*
No depression Ref
Possible depression 31%
Depression 72%
p for trend
Further adjusted for CVD risk factors†
No depression Ref
Possible depression 30%
Depression 65%
p for trend
Further adjusted for CAD severity score
No depression Ref
Possible depression 30%
Depression 73%
p for trend
No depression: BDI10 and no previous depression diagnosis; possible
and previous depression diagnosis. *Age, race (white vs. non-white), ed
vs. not married). †History of diabetes, history of hypertension, plasma
index, and current smoking.
CI  confidence interval; CVD  cardiovascular disease; Ref  refe
Relationship Between Depression Group, CRP, a
Table 3 Relationship Between Depression G
All Wo
HR 9
Unadjusted
No depression 1.00
Possible depression 1.12 0.6
Depression 2.58 1.4
Adjusted for demographic factors*
No depression 1.00
Possible depression 1.06 0.6
Depression 2.56 1.4
Further adjusted for CVD risk factors†
and CAD severity score
No depression 1.00
Possible depression 0.91 0.5
Depression 2.65 1.3
Further adjusted for CRP
No depression 1.00
Possible depression 0.92 0.5
Depression 2.43 1.2
No depression: BDI10 and no previous depression diagnosis; possible
and previous depression diagnosis. *Age, race (white vs. non-white), ed
vs. not married). †History of diabetes, history of hypertension, plasma choles
HR  hazard ratio; other abbreviations as in Tables 1 and 2.ontribution of depression and inflammation on CVD
utcomes (9). These authors found, consistent with our
esults, that depressive symptoms and inflammatory markers
ndependently predicted outcome and the estimate for
epression remained unchanged after adjusting for inflam-
atory Biomarkers
and Inflammatory Biomarkers
CI p Value
% Difference
in IL-6 95% CI p Value
— Ref — —
1.63 0.022 28% 1.10–1.49 0.001
2.32 0.0008 25% 1.01–1.52 0.036
0.0004 0.004
— Ref — —
1.65 0.022 27% 1.09–1.49 0.002
2.36 0.0008 28% 1.04–1.58 0.017
0.0004 0.002
— Ref — —
1.62 0.028 22% 1.05–1.43 0.010
2.27 0.002 22% 1.00–1.52 0.056
0.0008 0.013
— Ref — —
1.63 0.023 22% 1.05–1.43 0.010
2.36 0.0007 23% 1.00–1.52 0.046
0.0003 0.010
sion: BDI10 or previous depression diagnosis; depression: BDI10
(high school education vs. high school), andmarital status (married
terol and high-density lipoprotein cholesterol (HDL) levels, body mass
ategory; other abbreviations as in Table 1.
VD Incidence
, CRP, and CVD Incidence
 527) Women Without CAD (n  363)
p Value HR 95% CI p Value
— 1.00 — —
0 0.68 1.35 0.61–3.01 0.46
1 0.0009 4.09 1.91–8.75 0.0003
— 1.00 — —
0 0.84 1.42 0.63–3.18 0.40
2 0.001 4.21 1.93–9.18 0.0003
— 1.00 — —
0 0.74 1.16 0.50–2.69 0.72
4 0.003 4.23 1.81–9.88 0.0009
— 1.00 — —
2 0.77 1.12 0.48–2.59 0.79
7 0.008 3.82 1.60–9.09 0.002
sion: BDI10 or previous depression diagnosis; depression: BDI10
(high school education vs. high school), andmarital status (marriedamm
roup
95%
—
1.04–
1.25–
—
1.04–
1.25–
—
1.03–
1.21–
—
1.04–
1.26–
depres
ucation
cholesnd C
roup
men (n
5% CI
—
6–1.9
7–4.5
—
2–1.8
4–4.5
—
2–1.6
9–5.0
—
2–1.6
6–4.6
depres
ucationterol and HDL levels, body mass index, and current smoking.
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November 20, 2007:2044–50 Depression, Inflammation, and CVDation. Thus, on the basis of our results, also in women
oes inflammation contribute only modestly to the associ-
tion between depression and CVD.
epression and inflammation. The precise nature of the
elationship between depression and inflammation is not
lear. An obvious explanation is the higher prevalence of
oexisting risk factors and comorbidity in persons with
epression or a greater severity of atherosclerotic disease
21). Comorbid conditions and severity of CAD, however,
id not substantially affect the association between depres-
ion and inflammatory biomarkers in our study, and thus,
hese factors are not likely to play a major role. As with
ther forms of psychological stress (33,34), depression
ight induce inflammation through a number of mecha-
isms via sympathetic nervous system activation. For exam-
le, stress activates the transcription factor nuclear factor
appa B (NF-B) in peripheral blood mononuclear cells, an
ffect that is dependent on norepinephrine and is abolished
y alpha 1-adrenoceptor blockade (35). In addition, beta-
drenoceptor stimulation increases gene expression and
rotein production of several inflammatory cytokines (36).
nflammation might also play a role in the pathogenesis of
epression (37). Given the cross-sectional assessment of
epression and inflammatory biomarkers, our analysis can-
ot clarify the causal relationship between the two.
epression, inflammation, and CVD. The inter-relation-
hips among depression, inflammation, and incident CVD
r mortality also remain unclear and might be multi-
irectional (21). Depression might induce inflammation,
nd the latter might mediate or amplify the relationship
etween depression and CVD; however, a number of other
cenarios are possible. For example, both depression and
nflammation might cause CVD but through separate path-
ays. Alternatively, depression and inflammation might
ave a common precursor that is linked to CVD. Finally,
nflammation might cause both depression and CVD,
ithout depression having a causal role on CVD. We were
ble, in view of our prospective study design, to evaluate the
elative importance of depression and inflammation on
VD incidence. Our results indicate that depression and
nflammation act mostly independently of each other.
herefore, it is unlikely that depression is just an epiphe-
omenon of inflammation or that a common precursor to
oth depression and inflammation explains a large part of
heir association with CVD.
Taken together, our results suggest that, in women with
uspected coronary ischemia, depression and inflammation
nfluence CVD risk for the most part through independent
athways. Given the prognostic role of inflammatory bio-
arkers and their robust association with depression, it is
urprising that inflammation explained only a small fraction
f the increased CVD risk associated with depression. In
ontrast, the link between depression and CVD is multi-
actorial (7). For example, evidence is mounting on the role
f autonomic dysfunction and coagulation, which might provide alternative pathophysiological links between depres-
ion and CVD (38,39).
tudy limitations. We studied women referred for coro-
ary angiography due to suspected coronary ischemia;
herefore, our sample might not be generalizable to all
omen in the community or all women with heart disease.
owever, this is an important patient group to study, given
he high level of psychosocial distress in these patients and,
t the same time, their well-characterized CVD risk status,
ncluding severity of CAD measured by coronary angiogra-
hy. Another possible limitation is that the sample was
elatively heterogeneous, because it included both women
ith and without obstructive CAD. However, few women
n the WISE study were completely normal (i.e., had no
istory of coronary heart disease and also a normal angio-
ram) (29). To assess whether results would differ according
o whether women had or did not have obstructive CAD,
e repeated the analysis among women without CAD,
hich provided similar conclusions. Other limitations in-
lude delayed implementation of the psychosocial question-
aire reducing the sample size and the relatively low rate of
utcome events, thus precluding us from examining such
vents separately by type or cause. However, exploratory
nalyses showed similar trends of higher rates in the
epression group for almost all the cardiovascular events
hen examined separately. Additionally, we did not have
nformation on major depressive disorder from a diagnostic
nterview or on duration, severity, or type of treatment of
ast depression. However, our classification on the basis of
urrent depressive symptoms in conjunction with a previous
iagnosis of depression requiring treatment is presumably a
etter approximation of major depressive disorder than a
efinition focusing only on current depressive symptoms. It
s possible, however, that depression treatment is one reason
or the higher CVD risk in depressed women. Two recent
bservational studies have linked the use of selective sero-
onin reuptake inhibitor antidepressant drugs to a higher
ate of cardiovascular events and mortality in patients with
eart failure (40) and after bypass surgery (41). However,
hese results might be confounded by indication, because many
ther studies have documented the safety and possible benefit
f selective serotonin reuptake inhibitor use in cardiac patients
42,43), including 2 randomized trials (44,45). Although there
re some limitations, unique strengths of this study include the
ongitudinal design, multisite recruitment, richness of patient
ata, long-term follow-up, and core laboratory–blinded assess-
ents of coronary angiograms and inflammatory biomarkers.
onclusions
n women with suspected coronary ischemia, inflammation is
ndependently correlated with depression; however, it plays a
inor role in modulating the association between depression
nd CVD outcome events. Our results emphasize the need for
urther study to better understand the multifactorial patho-
hysiological pathways linking depression to CVD risk.
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